- Home
- MIRM vs TGL Comparison
MIRM vs TGL Comparison
Compare MIRM & TGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- TGL
- Stock Information
- Founded
- MIRM 2018
- TGL 2020
- Country
- MIRM United States
- TGL United States
- Employees
- MIRM N/A
- TGL N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- TGL Retail: Computer Software & Peripheral Equipment
- Sector
- MIRM Health Care
- TGL Technology
- Exchange
- MIRM Nasdaq
- TGL Nasdaq
- Market Cap
- MIRM 1.9B
- TGL N/A
- IPO Year
- MIRM 2019
- TGL 2022
- Fundamental
- Price
- MIRM $42.10
- TGL $2.20
- Analyst Decision
- MIRM Strong Buy
- TGL
- Analyst Count
- MIRM 11
- TGL 0
- Target Price
- MIRM $58.55
- TGL N/A
- AVG Volume (30 Days)
- MIRM 437.9K
- TGL 6.6M
- Earning Date
- MIRM 05-12-2025
- TGL 05-13-2025
- Dividend Yield
- MIRM N/A
- TGL N/A
- EPS Growth
- MIRM N/A
- TGL N/A
- EPS
- MIRM N/A
- TGL N/A
- Revenue
- MIRM $336,888,000.00
- TGL $2,398,398.00
- Revenue This Year
- MIRM $29.51
- TGL N/A
- Revenue Next Year
- MIRM $20.27
- TGL N/A
- P/E Ratio
- MIRM N/A
- TGL N/A
- Revenue Growth
- MIRM 80.76
- TGL N/A
- 52 Week Low
- MIRM $23.83
- TGL $1.71
- 52 Week High
- MIRM $54.23
- TGL $300.00
- Technical
- Relative Strength Index (RSI)
- MIRM 53.41
- TGL 35.95
- Support Level
- MIRM $38.22
- TGL $2.22
- Resistance Level
- MIRM $39.87
- TGL $2.77
- Average True Range (ATR)
- MIRM 1.92
- TGL 0.65
- MACD
- MIRM 0.49
- TGL 0.15
- Stochastic Oscillator
- MIRM 93.09
- TGL 20.52
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.